Melissa Baird - May 5, 2023 Form 4 Insider Report for Hims & Hers Health, Inc. (HIMS)

Role
Chief Operating Officer
Signature
/s/ Alexandra Cotter Wilkins, Attorney-in-Fact
Stock symbol
HIMS
Transactions as of
May 5, 2023
Transactions value $
-$382,482
Form type
4
Date filed
5/9/2023, 06:16 PM
Previous filing
Apr 10, 2023
Next filing
May 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HIMS Class A Common Stock Sale -$110K -9.13K -2.1% $12.04 426K May 5, 2023 Direct F1, F2
transaction HIMS Class A Common Stock Sale -$119K -9.9K -2.32% $12.04 417K May 5, 2023 Direct F1, F3
transaction HIMS Class A Common Stock Sale -$108K -9.13K -2.19% $11.83 407K May 8, 2023 Direct F1, F4
transaction HIMS Class A Common Stock Sale -$45.3K -3.83K -0.94% $11.83 404K May 8, 2023 Direct F1, F5
transaction HIMS Class A Common Stock Options Exercise $7.61K +19K +4.72% $0.40* 423K May 8, 2023 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HIMS Stock Option (right to buy) Options Exercise -$7.61K -19K -2.06% $0.40* 907K May 5, 2023 Class A Common Stock 19K $0.40 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2022 by the Reporting Person.
F2 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $11.74 - $12.23. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $11.76 - $12.245. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $11.69 - $12.03. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $11.73 - $12.00. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F6 The stock option exercises reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2022 by the Reporting Person.
F7 Prior to the Company's business combination transaction in 2021, the option represented the right to purchase 2,043,499 shares of Class A common stock of Hims, Inc., with an exercise price of $0.18. Following the Company's business combination transaction in 2021, the option converted into the right to purchase 1,086,723 shares of the Company with an exercise price of $0.40. 100% of the shares subject to the option have vested.